www.lightstonevc.com
Open in
urlscan Pro
34.82.93.76
Public Scan
Submitted URL: http://www.lightstonevc.com/
Effective URL: https://www.lightstonevc.com/
Submission: On December 27 via api from US — Scanned from DE
Effective URL: https://www.lightstonevc.com/
Submission: On December 27 via api from US — Scanned from DE
Form analysis 3 forms found in the DOM
#
<form action="#" class="form-companies js-form">
<span class="label">Filter by:</span>
<div class="wrap-select">
<div class="col">
<select name="sector" id="sector" class="jcf-hidden">
<option value="all">All Sectors</option>
<option value="biopharmaceuticals">Biopharmaceuticals</option>
<option value="medical-devices">Medical Technology</option>
</select><span class="jcf-select jcf-unselectable"><span class="jcf-select-text"><span class="">All Sectors</span></span><span class="jcf-select-opener"></span></span>
</div>
<div class="col">
<select name="company" id="company" class="jcf-hidden">
<option value="all">All Companies</option>
<option value="active">Active</option>
<option value="legacy-deals">Select Exits & IPOs</option>
</select><span class="jcf-select jcf-unselectable"><span class="jcf-select-text"><span class="">All Companies</span></span><span class="jcf-select-opener"></span></span>
</div>
<div class="col">
<select name="fund" id="fund" class="jcf-hidden">
<option value="all">All Funds</option>
<option value="legacy">Legacy</option>
<option value="lsv">Lightstone</option>
<option value="singapore">Singapore</option>
</select><span class="jcf-select jcf-unselectable"><span class="jcf-select-text"><span class="">All Funds</span></span><span class="jcf-select-opener"></span></span>
</div>
</div>
</form>#
<form action="#" class="form-people js-form">
<span class="label">Filter by:</span>
<div class="wrap-select">
<div class="col">
<select name="sector" id="sector2" class="jcf-hidden">
<option value="all">All Sectors</option>
<option value="biopharmaceuticals">Biopharmaceuticals</option>
<option value="medical-devices">Medical Technology</option>
</select><span class="jcf-select jcf-unselectable"><span class="jcf-select-text"><span class="">All Sectors</span></span><span class="jcf-select-opener"></span></span>
</div>
<div class="col">
<select name="office" id="office" class="jcf-hidden">
<option value="all">All Locations</option>
<option value="boston">Boston</option>
<option value="ireland">Dublin</option>
<option value="menlo-park">Menlo Park</option>
<option value="singapore">Singapore</option>
</select><span class="jcf-select jcf-unselectable"><span class="jcf-select-text"><span class="">All Locations</span></span><span class="jcf-select-opener"></span></span>
</div>
</div>
</form>POST /#wpcf7-f70-o1
<form action="/#wpcf7-f70-o1" method="post" class="wpcf7-form contact-form init" novalidate="novalidate" data-status="init">
<div style="display: none;">
<input type="hidden" name="_wpcf7" value="70">
<input type="hidden" name="_wpcf7_version" value="5.5.5">
<input type="hidden" name="_wpcf7_locale" value="en_US">
<input type="hidden" name="_wpcf7_unit_tag" value="wpcf7-f70-o1">
<input type="hidden" name="_wpcf7_container_post" value="0">
<input type="hidden" name="_wpcf7_posted_data_hash" value="">
</div>
<div class="row">
<p><span class="wpcf7-form-control-wrap text-393"><input type="text" name="text-393" value="" size="40" class="wpcf7-form-control wpcf7-text wpcf7-validates-as-required" aria-required="true" aria-invalid="false" placeholder="Name"></span>
</p>
</div>
<div class="row">
<span class="wpcf7-form-control-wrap email-795"><input type="email" name="email-795" value="" size="40" class="wpcf7-form-control wpcf7-text wpcf7-email wpcf7-validates-as-required wpcf7-validates-as-email" aria-required="true"
aria-invalid="false" placeholder="Email Address"></span>
<p></p>
</div>
<div class="row">
<span class="wpcf7-form-control-wrap textarea-331"><textarea name="textarea-331" cols="40" rows="10" class="wpcf7-form-control wpcf7-textarea wpcf7-validates-as-required" aria-required="true" aria-invalid="false"
placeholder="Your Message"></textarea></span>
<p></p>
</div>
<div class="row inn">
<input type="submit" value="Submit" class="wpcf7-form-control has-spinner wpcf7-submit"><span class="wpcf7-spinner"></span>
</div>
<div class="wpcf7-response-output" aria-hidden="true"></div>
</form>Text Content
menu * Approach * Portfolio * People * News * Contact Login * 1 * 2 * 3 * 4 * 5 WE BELIEVE IN FOUNDERS WITH VISION AND COMMITMENT. Hong I. Wan Tallac Therapeutics Portfolio WE BUILD EXCITING COMPANIES THAT CAN ACCOMPLISH BIG GOALS. Karun D. Naga The Foundry, LLC Approach WE FUND NOVEL, DISRUPTIVE TECHNOLOGIES TO TRANSFORM PATIENTS’ LIVES. Susan Molineaux Calithera Biosciences People WE ARE PARTNERS, COLLABORATORS, AND MENTORS. Adam D. Gridley Allay Therapeutics Portfolio OUR VISION IS BROAD, AND SO IS OUR COMMITMENT TO PATIENTS. Jaume Pons ALX Oncology Approach 100 Years of combined operational experience 20 IPOS 19 Acquisitions 2 Industries: Biotech & Medtech 1 Shared goal: bringing Impactful treatments To patients THE BEST PEOPLE, THE BEST SCIENCE. Our experienced life science investors seek out visionary founders to translate novel scientific breakthroughs into clinically and commercially meaningful therapies. Approach WE DON’T JUST INVEST IN IDEAS. WE INVEST IN PEOPLE. Lightstone Ventures was founded in 2012 to empower big-thinking founders with vision and commitment to bring innovative therapeutics to patients in need. What defines us: OUR EXPERIENCE SPANS ALL STAGES OF COMPANY GROWTH Our team collectively has nearly 100 years of company-building experience. We have been part of start-up ventures of all stages and played a critical role in evaluating, guiding, and building successful healthcare companies. WE ARE PARTNERS IN COMPANY BUILDING Fostering successful companies does not just mean writing a check. We not only back our companies financially, but we partner with them to navigate their day-to-day functions. Our team works hands-on with founders to help establish a strategy that can transform their vision into commercially viable products. MORE THAN INVESTORS – WE ARE GUIDES We invest with a long-term vision and patient capital that will fund the company through its life cycle from start-up to commercialization. Using a thesis-driven investment strategy, we focus on understanding key market sectors and seeking out disruptive technologies while building and nurturing relationships with key thought leaders. OUR REACH IS GLOBAL Our global footprint with offices in the U.S., Ireland and Singapore allows us to build a network with non-U.S. strategic and financial funding sources, as well as exploring novel development and commercialization strategies in these geographies. OUR PORTFOLIO COMPANIES SUCCEED Lightstone team members have been involved in some of the largest venture-backed life science exits over the last decade including: Ardian, Acceleron, ALX Oncology, Calithera BioSciences, Claret Medical, Disarm Therapeutics, MicroVention, Nimbus, Plexxikon, Portola Pharmaceuticals, Promedior, Proteolix, Ra Pharma, Tizona Therapeutics, Twelve and Zeltiq. Portfolio BIG IDEAS, BRIGHT FUTURES. We back driven entrepreneurs developing breakthrough therapies and technologies that have the potential to be industry-first or industry-leading products. The success of a company is determined by its people, so we work closely with biotech and medtech founders to build teams with the experience and ambition necessary to achieve their goals. BIOTECH Our team looks for companies developing first-in-class drugs, across all modalities including small molecules, biologics and cell and gene therapies. We are focused on several disease areas including the central nervous system (CNS), immunology with particular interest in autoimmune diseases, next-generation approaches in oncology and ophthalmology. MEDTECH We look for founders with big ideas targeting the convergence of technology, medicine and consumer health. We see promise in companies focused on personalized medicines and targeted therapeutics that leverage data analytics and scientific platforms—groundbreaking medical technologies that address major diseases across immunology, cardiovascular, neurology and ophthalmology. Filter by: All Sectors Biopharmaceuticals Medical Technology All Sectors All Companies Active Select Exits & IPOs All Companies All Funds Legacy Lightstone Singapore All Funds Biopharmaceuticals, Select Exits & IPOs, Legacy Acceleron Pharma is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat serious and rare diseases. The company successfully completed an IPO in 2013. www.acceleronpharma.com * Lead:Jean George * Fund:ATV * Location:Cambridge, MA Biopharmaceuticals, Active, Lightstone Alchemab Therapeutics is using deep learning and cutting edge science to develop novel drugs for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies and the adaptive immune system. alchemab.com * Lead:Jason Lettmann * Fund:LSV * Location:Cambridge, UK Biopharmaceuticals, Active, Singapore Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. www.allaytx.com * Lead:Mike Carusi * Fund:LSV * Location:Menlo Park, CA and Singapore Biopharmaceuticals, Select Exits & IPOs, Lightstone ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. The company successfully completed an IPO in 2020 (NASDAQ: ALXO). alxoncology.com * Lead:Jason Lettmann * Fund:LSV * Location:Dublin, Ireland Medical Technology, Active, Lightstone Apreo Health is a development stage medical technology company that is developing innovative, globally applicable treatments for pulmonary disease. thefoundry.com * Lead:Hanson S. Gifford, III * Fund:LSV * Location:Menlo Park, CA Medical Technology, Select Exits & IPOs, Legacy Ardian is a medical device company developing catheter-based therapies to treat hypertension and related conditions. Ardian was incubated within The Foundry, the premier medical technology incubator, and was acquired by Medtronic (NYSE: MDT) in 2011. * Lead:Hank Plain, Mike Carusi * Fund:ATV, Morgenthaler * Location:Mountain View, CA Biopharmaceuticals, Active, Lightstone Atsena Therapeutics is a clinical-stage gene therapy company focused on developing novel therapeutics to prevent or reverse blindness. atsenatx.com * Lead:Jason Lettmann * Fund:LSV * Location:Boston, MA Biopharmaceuticals, Select Exits & IPOs, Legacy Avidia is a biopharmaceutical company discovering and developing a new class of human therapeutic proteins called Avimer™. The company was acquired by Amgen (NASDAQ: AMGN) in 2006. amgen.com * Fund:Morgenthaler * Location:Mountain View, CA Medical Technology, Select Exits & IPOs, Legacy Cabochon Aesthetics is a medical device company developing effective, scientific solutions for the aesthetic treatment of cellulite. The company was incubated within The Foundry, the premier medical technology incubator, and was acquired by Ulthera in 2014. * Lead:Hank Plain * Fund:Morgenthaler Medical Technology, Active, Lightstone Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. Its lead product, Cala Trio™, is the only non-invasive prescription therapy for essential tremor and is now available through a unique digital business model of direct-to-patient solutions. calahealth.com * Lead:Mike Carusi * Fund:LSV * Location:Burlingame, CA Biopharmaceuticals, Select Exits & IPOs, Legacy Calithera Biosciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company successfully completed an IPO in 2014. Morgenthaler Ventures has exited the investment since IPO. calithera.com * Lead:Jean George * Fund:ATV, Morgenthaler * Location:South San Francisco, CA Medical Technology, Active, Lightstone Developing the next generation of percutaneous left ventricular assist devices. cardiacbooster.com * Lead:Mark Deem * Fund:LSV * Location:The Netherlands Biopharmaceuticals, Active, Lightstone Carrick Therapeutics is a biopharmaceutical company pioneering a portfolio of unique, first in class cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. carricktherapeutics.com * Lead:Jason Lettmann * Fund: LSV * Location:Dublin, Ireland Biopharmaceuticals, Active, Lightstone Catamaran Bio is a biopharmaceutical company developing next generation NK cell therapy platform with a predominant focus on solid tumors. The company was founded by SV Health Investors alongside academic founders Branden Moriarty and Catherine Bollard. * Lead: Caroline Gaynor * Fund:LSV Biopharmaceuticals, Active, Lightstone Cerevance is a biopharmaceutical company that is taking a novel approach to the discovery and development of therapeutics for CNS and psychiatric diseases utilizing its powerful NETSseq target discovery platform. cerevance.com * Lead:Jason Lettmann * Fund:LSV * Location:Boston, MA Medical Technology, Select Exits & IPOs, Lightstone Claret Medical is a medical device company developing innovative solutions for cerebral protection during structural heart and vascular interventions. The company was acquired by Boston Scientific (NYSE: BSX) in 2018. claretmedical.com * Lead:Hank Plain * Fund:LSV * Location:Santa Rosa, CA Medical Technology, Active, Lightstone Contego Medical is a Raleigh-based medical device company developing a suite of products for the treatment of neurovascular, coronary and peripheral vascular disease. * Lead: Hanson S. Gifford, III * Fund:LSV Biopharmaceuticals, Select Exits & IPOs, Lightstone Cyteir Therapeutics is a biopharmaceutical company and a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases. The company successfully completed an IPO in 2021 (NASDAQ: CYT). cyteir.com * Lead: Jean George * Fund:LSV * Location: Cambridge, MA Biopharmaceuticals, Select Exits & IPOs, Lightstone Disarm Therapeutics is a biotechnology company that is creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disease-causing disability and disease progression. The company was acquired by Eli Lilly and Company (NYSE: LLY) in 2020. disarmtx.com * Lead:Jean George * Fund:LSV * Location:Cambridge, MA Medical Technology, Active, Lightstone EarLens is a medical device company developing next generation hearing technology that uses light to transmit sound and energy directly to the eardrum enabling users to appreciate high frequency sounds and improved speech recognition, especially in noisy environments. earlens.com * Lead:Hank Plain * Fund:LSV * Location:Redwood City, CA Biopharmaceuticals, Active, Legacy Elcelyx Therapeutics is a biopharmaceutical company developing therapeutic agents based on the finding that modulation of the neuro-enteroendocrine system of the gut, including L-cells, amplifies the release of hormones such as those that play an important role in glucose regulation. elcelyx.com * Fund:Morgenthaler * Location:San Diego, CA Medical Technology, Active, Legacy EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based and incisionless surgical technology for the treatment of GERD. www.endogastricsolutions.com * Lead:Mike Carusi * Fund:ATV * Location:Redwood City, CA / Redmond, WA Medical Technology, Active, Lightstone FIRE1 is a medical device company developing novel remote monitoring devices to improve patient quality of life and outcomes while lowering overall healthcare costs. fire1foundry.com * Lead:Jason Lettmann * Fund:LSV * Location:Dublin, Ireland Biopharmaceuticals, Select Exits & IPOs, Legacy FivePrime Therapeutics is a biopharmaceutical company focused on the discovery and development of a complete range of innovative protein and antibody drugs. The company successfully completed an IPO in 2013. www.fiveprime.com * Lead:Jean George * Fund:ATV * Location:Boston, MA Biopharmaceuticals, Select Exits & IPOs, Lightstone Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated initial human efficacy related to muscle cramping. The company successfully completed an IPO in 2015. flex-pharma.com * Lead:Jean George * Fund:LSV * Location:Boston, MA Biopharmaceuticals, Select Exits & IPOs, Legacy FoldRx Pharmaceuticals is a biopharmaceutical company developing disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The company was acquired by Pfizer (NYSE: PFE) in 2010. * Fund:Morgenthaler * Location: Cambridge, MA Medical Technology, Select Exits & IPOs, Legacy ForSight VISION2 is a medical device company that developed a proprietary ocular punctal plug drug delivery system. The company was acquired by QLT Inc. (NASDAQ: QLTI) in 2007. * Fund:Morgenthaler * Location:Menlo Park, CA Medical Technology, Select Exits & IPOs, Legacy ForSight VISION4 is a medical device company developing novel drug delivery therapies for the treatment of retinal diseases. The company was incubated within ForSight Labs and was acquired by Roche (OTCQX: RHHBY) in 2017. * Fund:Morgenthaler * Location:Menlo Park, CA Medical Technology, Select Exits & IPOs, Legacy ForSight VISION5 is a medical device company focused on a novel anterior segment drug delivery program for ophthalmic drugs. The company was incubated within ForSight Labs and was acquired by Allergan (NYSE: AGN) in 2016. * Fund:Morgenthaler * Location:Menlo Park, CA Biopharmaceuticals, Select Exits & IPOs, Lightstone, Singapore Gemini Therapeutics is a precision medicine company developing a broad, multimodal pipeline of first-in-class therapeutics for genetically-defined age-related macular degeneration and rare diseases. geminitherapeutics.com * Lead: Jean George * Fund:LSV, LSV Singapore * Location:Cambridge, MA Medical Technology, Active, Legacy Gynesonics is a medical device company focused on advancing women’s health by developing minimally invasive, transcervical, uterus-preserving and incision-free technologies for diagnostic and therapeutic applications. gynesonics.com/us * Lead:Mike Carusi * Fund:ATV * Location:Redwood City, CA Biopharmaceuticals, Select Exits & IPOs, Legacy Hypnion is a biopharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders such as sleep, wake-alertness disorders and circadian rhythm abnormalities. The company was acquired by Eli Lilly (NYSE: LLY) in 2007. * Lead:Jean George * Fund:ATV * Location: Lexington, MA Biopharmaceuticals, Active, Singapore Ligature is an early stage biopharmaceutical company focused on the research and development of small molecule drugs designed to degrade undruggable disease-causing proteins with precision, delivering new therapies for intractable cancers. ligaturetx.com * Lead: Kenneth D. Noonan, Ph.D., Wen Qi Ho, Ph.D. * Fund: LSV Singapore * Location:Singapore Biopharmaceuticals, Active, Lightstone, Singapore Locanabio is an RNA-targeting gene therapy company with a platform technology to address a wide spectrum of human genetic diseases. locanabio.com * Lead:Jean George * Fund:LSV, LSV Singapore * Location:San Diego, CA Biopharmaceuticals, Active, Singapore MediSix Therapeutics is an early-stage cell therapy company that is taking a novel approach to develop chimeric antigen receptor (“CAR”) T cells to target T cell lymphoma and leukemia. medisixtx.com * Lead:Mike Carusi, Christina Isacson, Ph.D. * Fund: LSV Singapore * Location:Boston, MA and Singapore Medical Technology, Select Exits & IPOs, Legacy MicroVention is a medical device company developing and marketing innovative neuroendovascular technologies for the treatment of vascular diseases in small vessels. The company was acquired by Terumo (TYO: 4543) in 2006. www.microvention.com * Lead:Mike Carusi * Fund:ATV * Location:Tustin, CA Biopharmaceuticals, Select Exits & IPOs, Legacy Morphotek is a biopharmaceutical company developing novel classes of biological-based products to treat cancer, inflammation and infectious diseases. The company was acquired by Eisai Inc. (TYO: 4523) in 2007 * Fund:Morgenthaler * Location:Exton, PA Medical Technology, Active, Legacy Moximed is a medical device company that is developing innovative devices for patients with osteoarthritis of the knee. The company was incubated within the ExploraMed incubator. moximed.com * Fund:Morgenthaler * Location:Hayward, CA Biopharmaceuticals, Active, Select Exits & IPOs, Lightstone Nimbus Therapeutics is a biotechnology company focused on designing highly selective and potent medicines to disrupt known drivers of serious diseases. The company was formed using an LLC model. Its lead program was acquired by Gilead Sciences (NASDAQ: GILD) in 2016. www.nimbustx.com * Lead:Jean George * Fund:LSV * Location:Cambridge, MA Medical Technology, Active, Legacy, Lightstone Nuvaira is a medical device company developing novel devices for treating obstructive lung diseases. The company was incubated within The Foundry, the premier medical technology incubator. www.nuvaira.com * Lead:Mike Carusi, Hank Plain * Fund:ATV, Morgenthaler, LSV * Location:Minneapolis, MN Biopharmaceuticals, Select Exits & IPOs, Legacy Orexigen Therapeutics is a biopharmaceutical company developing therapies for the treatment of obesity. The company successfully completed an IPO in 2007. www.nalpropion.com * Fund:Morgenthaler * Location:La Jolla, CA Biopharmaceuticals, Active, Lightstone A NewCo focused on developing novel autoimmune therapies. * Lead:Caroline Gaynor * Fund:LSV * Location:Dublin, Ireland Biopharmaceuticals, Select Exits & IPOs, Legacy Plexxikon is a biotechnology company developing novel small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to develop a portfolio of competitively differentiated therapeutic programs. The company was acquired by Daiichi Sankyo (TYO: 4568) in 2011 plexxikon.com * Lead:Mike Carusi Biopharmaceuticals, Select Exits & IPOs, Legacy Portola Pharmaceuticals is a biopharmaceutical company developing innovative therapeutics for cardiovascular and autoimmune/inflammatory diseases. The company successfully completed an IPO in 2013. portola.com * Lead:Jean George * Location:South San Francisco, CA Medical Technology, Select Exits & IPOs, Legacy PowerVision is a medical device company developing a proprietary fluid-controlled accommodating intraocular lens (IOL) technology to restore the vision of youth to millions of middle-aged or elderly individuals. The company was acquired by Alcon (NYSE: ALC) in 2019 powervisionlens.com * Lead:Mike Carusi * Fund: ATV * Location:Belmont, CA Biopharmaceuticals, Select Exits & IPOs, Legacy Principia Biopharma is a biopharmaceutical company developing novel compounds with enhanced sensitivity, high potency and longer duration of effect. Principia was acquired by Sanofi (NASDAQ: SNY) in 2020. principiabio.com * Fund:Morgenthaler * Location:Menlo Park, CA Biopharmaceuticals, Select Exits & IPOs, Legacy Promedior is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. The company was acquired by Roche Holding (OTCMKTS: RHHBY) in 2019. promedior.com * Lead:Jason Lettmann * Fund:Morgenthaler * Location:Lexington, MA Biopharmaceuticals, Select Exits & IPOs, Legacy Proteolix is a biopharmaceutical company developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. The company was acquired by Onyx Pharmaceuticals (NASDAQ: ONXX) in 2009. onyx.com * Lead:Jean George * Fund:ATV * Location:South San Francisco, CA Medical Technology, Active, Lightstone Proverum is an Irish medical device company founded in 2016 as a spin-off from Trinity College Dublin. The company is developing a novel treatment solution for patients with symptomatic BPH designed to be safely and effectively performed in a doctor’s office setting in a simple procedure under local anaesthesia. LSV invested in 2022 to support the Company through its pivotal trial and pursuit of regulatory approval for the ProVee system in Europe and the US. proverummedical.com * Lead:Caroline Gaynor * Location:Dublin, Ireland Biopharmaceuticals, Select Exits & IPOs, Lightstone Ra Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of drugs with the specificity of antibodies and the oral bioavailability of small molecules. The company successfully completed an IPO in 2016. rapharma.com * Location:Cambridge, MA Medical Technology, Active, Legacy, Lightstone Relievant Medsystems is a medical device company developing a new, minimally invasive technology that targets the source of chronic low back pain with a simple one-hour treatment. relievant.com * Lead:Jason Lettmann * Fund:Morgenthaler, LSV * Location:Redwood City, CA Medical Technology, Active, Lightstone Reprieve Cardiovascular is a medical device company focused on automated fluid management technologies for acute heart failure treatment. reprievecardio.com * Lead: Hanson S. Gifford, III * Fund:LSV * Location:Milford, MA Biopharmaceuticals, Select Exits & IPOs, Legacy Scioderm is a clinical-stage biopharmaceutical company developing innovative therapies to address diseases with high unmet need, including rare diseases. The company was acquired by Amicus Therapeutics (NASDAQ: FOLD) in 2015. * Fund:Morgenthaler * Location:Durham, NC Biopharmaceuticals, Active, Legacy Second Genome is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics identified using microbiome science. secondgenome.com * Lead:Mike Carusi, Jason Lettmann * Fund:ATV, Morgenthaler * Location:San Bruno, CA Medical Technology, Active, Legacy SetPoint Medical is a clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases. setpointmedical.com * Lead:Hank Plain * Fund:Morgenthaler * Location:Valencia, CA Medical Technology, Active, Lightstone Shoulder Innovations, Inc. is a medical device company developing and commercializing an innovative shoulder replacement system which addresses the greatest cause of surgical failure: glenoid loosening. This improved system is expected to improve patient outcomes and reduce overall system costs. shoulderinnovations.com * Lead:Mike Carusi * Fund:LSV * Location:Holland, MI Medical Technology, Active, Legacy Spine Wave is a medical device company developing and marketing novel devices for spine surgery, specifically spinal fusion, vertebral compression fracture repair and nucleus replacement and augmentation spinewave.com * Fund:Morgenthaler * Location:Shelton, CT Biopharmaceuticals, Active, Lightstone Tallac Therapeutics is a biopharmaceutical company focused on the research and development of CpG-Antibody conjugates intended to stimulate the immune system in the treatment of cancer. tallactherapeutics.com * Lead:Mike Carusi * Fund:LSV * Location:Burlingame, CA Biopharmaceuticals, Select Exits & IPOs, Legacy Threshold Pharmaceuticals is a biotechnology company developing therapeutics based on tumor hypoxia, a platform that offers potential to treat most solid tumors. The company successfully completed an IPO in 2005. * Fund:Morgenthaler * Location:South San Francisco, CA Biopharmaceuticals, Select Exits & IPOs, Lightstone Tizona Therapeutics is a clinical-stage immunotherapy company harnessing the power of the immune system to develop treatments for cancer. In 2020, Gilead Sciences (NASDAQ: GILD) purchased an option to acquire ~50% of the company. tizonatx.com * Lead:Jean George * Fund:LSV * Location:South San Francisco, CA Medical Technology, Select Exits & IPOs, Legacy Transcend Medical is a medical device company focused on the development of devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. The company was acquired by Alcon (Novartis) (NYSE: NVS) in 2016. * Fund:Morgenthaler * Location:Menlo Park, CA Biopharmaceuticals, Active, Lightstone Trishula Therapeutics is a clinical stage company dedicated to the development of TTX-030, a first-in-class, anti-CD39 antibody being studied in advanced cancers in multiple indications. In 2020, the company was spun off from Tizona Therapeutics when Gilead Sciences (NASDAQ: GILD) purchased an option to acquire ~50% of Tizona. www.trishulatx.com * Lead:Jean George * Fund:LSV * Location:South San Francisco, CA Biopharmaceuticals, Active, Lightstone Trotana Therapeutics is a San Diego based biotech company dedicated to the discovery and development of medicines targeting RNA binding proteins. trotana.com * Lead: Jean George * Location:San Diego, CA Medical Technology, Select Exits & IPOs, Legacy Twelve is a medical device company developing a novel device for the treatment of chronic cardiovascular disease. The company was incubated within The Foundry, the premier medical technology incubator, and was acquired by Medtronic (NYSE: MDT) in 2015 * Lead:Hank Plain * Location:Menlo Park, CA Medical Technology, Select Exits & IPOs, Legacy Vapotherm is a medical device company pioneering Hi-VNI technology, a less invasive form of support for patients in respiratory distress. The company successfully completed an IPO in 2018. vapotherm.com * Lead:Jason Lettmann * Fund:Morgenthaler * Location:Exeter, NH Biopharmaceuticals, Select Exits & IPOs, Legacy Verastem is a biopharmaceutical company bringing breakthroughs in cancer stem cell research into new medicines for the treatment of major cancers, such as breast cancer. The company successfully completed an IPO in 2012. verastem.com * Lead:Jean George * Fund:ATV * Location:Cambridge, MA Biopharmaceuticals, Select Exits & IPOs, Lightstone Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Vigil’s purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. Vigil is utilizing modern neuroscience drug development across multiple therapeutic modalities to deliver precision-based therapies to improve the lives of patients and their families. The company successfully completed an IPO in 2022 (NASDAQ: VIGL). vigilneuro.com * Lead:Christina Isacson, Ph.D. * Fund:LSV * Location:Cambridge, MA Medical Technology, Active, Lightstone Willow is a medical device company commercializing a wearable breast pump that allows women to achieve their breastfeeding goals without pressing pause on their own lives. The company, formerly known as NC7, was incubated within ExploraMed. shop.willowpump.com * Lead:Mike Carusi * Fund:LSV * Location:Mountain View, CA Medical Technology, Select Exits & IPOs, Legacy ZELTIQ is a medical device company developing and marketing a non-invasive, office-based procedure that uses Cryolipolysis, a proprietary cooling technology, to eliminate fat. The company successfully completed an IPO in 2011. coolsculpting.com * Lead:Jean George * Fund:ATV * Location:Pleasanton, CA People A COMMON PASSION FOR UNCOMMON DISCOVERIES. We are like-minded collaborators with a shared purpose: to integrate business and science into breakthrough companies that can change the lives of patients. Filter by: All Sectors Biopharmaceuticals Medical Technology All Sectors All Locations Boston Dublin Menlo Park Singapore All Locations Mike Carusi General Partner Mike Carusi General Partner Mike Carusi General Partner Mike is a General Partner and Team Leader of Lightstone Ventures (LSV) and focuses on investments in the biopharmaceutical and medical device sectors. He is based in the firm’s Menlo Park, CA office, where he also serves as a General Partner at Advanced Technology Ventures (ATV). His representative investments include Allay Therapeutics, Altura Medical (acquired by Lombard), Ardian (acquired by Medtronic), Cala Health, EndoGastric Solutions, Gynesonics, MediSix Therapeutics, MicroVention (acquired by Terumo), Nuvaira, Plexxikon (acquired by Daiichi Sankyo), PowerVision (acquired by Alcon), Second Genome, Shoulder Innovations, Tallac Therapeutics, and Willow. Featured on the Forbes Midas List of top technology and life science investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare conferences. He serves as an Adjunct Professor at the Tuck School of Business Administration at Dartmouth College. In addition, Mike has been heavily involved with several programs at Stanford University including the Stanford Biodesign Program and, more recently, the Stanford Center for Clinical and Translational Research and Education (Spectrum). Lastly, Mike served as a Director on the National Venture Capital Association (NVCA) Board of Directors and remains active in helping to shape policy affecting both innovation and healthcare. Earlier in his career, Mike served as a Director of Business Development for Inhale Therapeutic Systems (now Nektar Therapeutics, NASDAQ: NKTR), a venture-backed pulmonary drug delivery company that went public in 1994. At Inhale, Mike led partnering activities with a number of pharmaceutical and biotechnology companies in the U.S., Europe, and Japan. Mike also was a Principal at The Wilkerson Group, a leading management consulting firm focused exclusively on healthcare. At The Wilkerson Group, Mike helped establish the firm’s offices in London and San Francisco. * Education: M.B.A. from the Tuck School of Business B.S. in Mechanical Engineering from Lehigh University * Sector: Biopharmaceuticals, Medical Technology * Location: Menlo Park REPRESENTATIVE INVESTMENTS: * Allay Therapeutics * Ardian * Cala Health * Endogastric Solutions * Gynesonics * MediSix Therapeutics * MicroVention * Nuvaira * Plexxikon * Powervision * Second Genome * Shoulder Innovations * Tallac Therapeutics * Willow Jean George General Partner Jean George General Partner Jean George General Partner Jean is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston office, where she also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma (NASDAQ: XLRN), Calithera Biosciences (NASDAQ: CALA), Cyteir Therapeutics, Disarm Therapeutics (acquired by Eli Lilly), Flex Pharma (NASDAQ: FLKS), Five Prime Therapeutics (NASDAQ: FPRX), Gemini Therapeutics, Hypnion (acquired by Eli Lilly), Locanabio Therapeutics, Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapetics (acquired by Gilead), Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ). Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. Prior to LSV and ATV, Jean worked for BancBoston Ventures and led its life sciences investments in Neurometrix (NASDAQ:NURO), Ironwood Pharmaceuticals (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters) and Syntonix Pharmaceuticals (acquired by Biogen/Idec). She has been in the biopharmaceutical industry for over 30 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also was Vice President and Founder of Genzyme’s Tissue Repair Division. Previously, Jean spent six years working in chemistry and bioresearch. * Education: M.B.A. from Simmons College Graduate School of Management B.S. from the University of Maine * Sector: Biopharmaceuticals * Location: Boston REPRESENTATIVE INVESTMENTS: * Acceleron Pharma * Calithera Biosciences * Cyteir Therapeutics * Disarm Therapeutics * FivePrime Therapeutics * Flex Pharma * Gemini Therapeutics * Hypnion * Locanabio * Nimbus Therapeutics * Portola Pharmaceuticals * Proteolix * Tizona Therapeutics * Trotana Therapeutics * Verastem * ZELTIQ Jason Lettmann General Partner Jason Lettmann General Partner Jason Lettmann General Partner Jason Lettmann is a General Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical and medical technology sectors. Jason brings 20 years of operating and venture experience in the life sciences and also is a General Partner at Morgenthaler Ventures. He currently serves on the Board of Directors of ALX Oncology (NASDAQ: ALXO), Atsena Therapeutics, Carrick Therapeutics, Cerevance, FIRE1, Relievant Medsystems, and Second Genome. Jason led the firm’s investments and served as a Director of Ra Pharmaceuticals (acquired by UCB) and Vapotherm (NASDAQ: VAPO). Jason also served as the interim CEO of Promedior and led the company through its sale to Roche in 2020. In 2014, Jason established Lightstone’s Europe office located in Dublin, Ireland, to expand the firm’s investment activities to Europe and currently serves as Director of Lightstone Capital Management Ireland Ltd. Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage investments in the life sciences. During his time at Split Rock, Jason was actively involved with the firm’s investment in Ardian (acquired by Medtronic), Cabochon Aesthetics (acquired by Ulthera), Atritech (acquired by Boston Scientific), Entellus Medical (acquired by Stryker), Evalve (acquired by Abbott), and Transcend Medical (acquired by Alcon). Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013. Prior to venture, Jason’s experience includes tenure with Guidant’s Compass Group which focused on corporate venture investing and business development, as well as a consultant with Accenture’s Health and Life Science practice, where he advised clients across the medical device, pharmaceutical, and healthcare payer sectors. Jason also previously worked as a Genetic Research Analyst at the University of Iowa Hospitals and Clinics. * Education: M.B.A. with distinction from the University of Michigan’s Ross School of Business B.A. with honors from the University of Iowa * Sector: Biopharmaceuticals, Medical Technology * Location: Menlo Park REPRESENTATIVE INVESTMENTS: * Alchemab Therapeutics * ALX Oncology * Atsena Therapeutics * Carrick Therapeutics * Cerevance * FIRE1 * Promedior * Ra Pharmaceuticals * Relievant Medsystems * Second Genome * Vapotherm Hank Plain Special Partner Hank Plain Special Partner Hank Plain Special Partner Hank Plain is a Special Partner of Lightstone Ventures. He also serves as a General Partner at Morgenthaler Ventures, which he joined in 2007 after more than 25 years in the pharma and medical device industry. Mr. Plain began his career in 1980 with Eli Lilly. He left Lilly to become CEO of Perclose, where he led the company through a successful IPO and acquisition by Abbott Laboratories in 1999. Prior to becoming a venture capitalist, he co-founded eight medical device companies along with the team at The Foundry medical device incubator. Mr. Plain serves on the boards of Earlens, Nuvaira, Moximed and Setpoint. He previously served on the boards of nine companies that were acquired – Claret Medical, Miramar Labs, Twelve Medical, Ardian, Access Closure, Acclarent, Cabochon, EPI and TransVascular. Mr. Plain is Chairman of the Board of Trustees for the Naval Postgraduate School Foundation in Monterey, CA and serves on the board of the First Tee of Monterey County. * Education: B.S. in Finance from University of Missouri * Sector: Medical Technology * Location: Menlo Park REPRESENTATIVE INVESTMENTS: * Ardian * Cabochon Aesthetics * Claret Medical * EarLens * Nuvaira * SetPoint Medical * Twelve Hanson S. Gifford, III Partner Hanson S. Gifford, III Partner Hanson S. Gifford, III Partner Hanson is a Partner of LSV. He assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. He has served in this role since November 2013. Hanson is also a Managing Partner at The Foundry, LLC, a medical device company incubator and a preferred partner to LSV. Since its inception in 1998, Hanson has led The Foundry in all of its activities. These include the invention, identification and development of new technologies, the formation, financing, and staffing of over twenty new companies, and ongoing support of these new ventures as a board member. Success stories include Evalve (acquired by Abbott), Concentric (acquired by Stryker), Ardian (acquired by Medtronic), Twelve (acquired by Medtronic). At ForSight Labs, an Ophthalmology-focused incubator started by Hanson, Eugene de Juan, MD, and K. Angela Macfarlane, successes include Transcend Medical (acquired by Alcon), Forsight Newco 2 (acquired by QLT), Forsight Vision 4 (acquired by Genentech/Roche), and Forsight Vision 5 (acquired by Allergan). Prior to The Foundry, Hanson was Vice President of Research and Development at Heartport, Inc., which had a successful IPO in 1996. From 1993-1998, he built and led a 62-person team at Heartport developing a wide variety of novel devices and procedures for minimally invasive cardiac surgery. In 1992-1993, Hanson co-founded and served as Managing Director of Bavaria Medizin Technologie, GmbH in Oberpfaffenhofen, Germany. In 1991, Hanson co-founded and served as President of Cardiovascular Therapeutic Technologies (acquired by Eli Lilly). From 1985-1990, Hanson worked at Devices for Vascular Intervention (acquired by Eli Lilly) in various engineering, clinical research and marketing capacities. Before joining DVI, Hanson worked in engineering roles at Oximetrix and General Dynamics. Hanson is a named inventor on over 370 issued US patents. Hanson is a Director of FIRE1, Contego, Reprieve Cardiovascular, Half Moon Medical, Tangible Science, Apreo Health, and Mavericks Endo. * Education: B.S. in Mechanical Engineering from Cornell University * Sector: Medical Technology * Location: Menlo Park REPRESENTATIVE INVESTMENTS: * Contego Medical * Reprieve Cardiovascular Christina Isacson, Ph.D. Partner Christina Isacson, Ph.D. Partner Christina Isacson, Ph.D. Partner Christina Isacson is a Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical sector. Christina has spent nearly 20 years in the biotech industry across operational roles and in venture capital. She brings experience in creating, launching, building and operating early stage biotechnology companies including Magenta Therapeutics (NASDAQ:MGTA) and Decibel Therapeutics (NASDAQ:DBTX). Before joining Lightstone in 2021, Christina was part of the founding team and Chief Business Officer at Magenta Therapeutics where she was accountable for portfolio strategy and management, program management, business development, alliance management and commercial strategy. Prior to Magenta, Christina was Principal at Third Rock Ventures, an early-stage life sciences venture capital firm. At Third Rock, Christina focused on new company formation, due diligence, and led business development efforts more broadly on behalf of Third Rock. Prior to being part of the founding teams of Magenta and Decibel, Christina held operational roles at Ironwood Pharmaceuticals (NASDAQ:IRWD) in corporate development. In addition, she has held venture roles with Boston University’s Technology Development Fund and with Accelerator Corp (Fund I). Originally trained as a Ph.D. in Neuroscience, leading the integration of science and medicine with business is a fundamental objective in her career. * Education: Ph.D. Neuroscience from Tufts University School of Medicine, Graduate School of Biomedical Sciences B.Sc. Biology from McGill University * Sector: Biopharmaceuticals * Location: Boston REPRESENTATIVE INVESTMENTS: * Vigil Neuroscience Mark Deem Operating Partner Mark Deem Operating Partner Mark Deem Operating Partner Mark is an Operating Partner of LSV. He assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. He has served in this role since November 2013. Mark is a co-founder of the Foundry, LLC. The Foundry is the premier medical device company incubator and a preferred partner to LSV. Since its inception in 1998, The Foundry has founded and financed over twenty new medical device companies. Success stories include Twelve (acquired by Medtronic), Ardian (acquired by Medtronic), eValve (acquired by Abbott), and Concentric (acquired by Stryker). Mark joined The Foundry at its inception in 1998. In addition to spearheading the research and invention process on new clinical opportunities, Mark led the early stage effort in The Foundry’s new companies until the company’s CEO and Senior Staff was hired. Prior to joining The Foundry, Mark served in a founding role as consulting Director of Research and Development for Ventrica, Inc. Previously, Mark was a senior member of the Research & Development team at Medtronic Micro Interventional Systems. Mark joined MIS as one of the initial members of the company’s engineering team and remained there through the acquisition by Medtronic. Previously, Mark held engineering positions with Devices for Vascular Engineering, Cordis Corporation and the USCI Division of C.R. Bard. Mark has spent over thirty years in the design, testing and manufacture of medical devices. He is a co-inventor on over 250 issued and pending U.S. patents. Mark serves as Chairman of the Board for Allay Therapeutics (formerly Foundry Therapeutics 1), is a Director for FIRE1, and Half Moon Medical and is a board observer for Nuvaira and Shoulder Innovations. * Education: B.S. in Biomedical Engineering from Boston University * Sector: Medical Technology * Location: Menlo Park Stacy Enxing Seng Operating Partner Stacy Enxing Seng Operating Partner Stacy Enxing Seng Operating Partner Stacy is an Operating Partner of LSV and assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. She joined the LSV team in March 2016. Since 2013, Stacy has also focused her work on engaging as a Professional Director, serving as an Independent Director and Committee Member for both public and venture-backed private companies across the healthcare ecosystem. Stacy currently serves as a non-executive Independent Director and member of the Compensation and Management Committee for Hill-Rom Holdings, Inc. (NYSE: HRC), Sonova Holding AG (VTX: SOON), and LivaNova, Inc. (NASDAQ: LIVN). Stacy also serves as Chairwoman of the Board for both CALA Health and Contego, an Independent Director for Vesper Medical, as well as a Director for the Fogarty Institute, a non-profit educational innovator. Past Director appointments include PreCARDIA Inc, (exited to Abiomed), Claret Inc, (exited to Boston Scientific), Spirox, (exited to Entellus/Abbott) FIRE 1, (Covidien/Medtronic Investment), CVI (exited to Covidien/Medtronic) and Solace Therapeutics. An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and world-class company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture. Prior to Independent Director work, Stacy served as the President of Covidien’s $1.7B Vascular Therapies business. Stacy joined Covidien following its $2.6B acquisition of ev3 Inc., a medical technology start-up that Stacy co-created in 2000 with ev3’s founding team. Over the course of her career, Stacy has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions, and under her operating leadership, a reputation of achieving world class customer and employee engagement. Stacy’s earlier work in medtech included sales and marketing leadership roles with SCIMED/Boston Scientific and sales and product management roles with American Hospital Supply/Baxter. * Education: B.A. in Public Policy from Michigan State University M.B.A. from Harvard University Executive Course on Governance from Stanford Business School * Sector: Medical Technology * Location: Menlo Park Brendan Kelly, Ph.D. Vice President Brendan Kelly, Ph.D. Vice President Brendan Kelly, Ph.D. Vice President Brendan is a Vice President at Lightstone Ventures evaluating opportunities in the biopharmaceutical sector. Brendan has a background in medicinal chemistry and computational drug discovery research, and life sciences strategy. Prior to Lightstone, Brendan was Director of New Product Planning at Q32 Bio, where he helped to define value propositions and commercial strategy for the company’s lead assets and discovery platform. Brendan was previously a life sciences strategy consultant at L.E.K. Consulting, working on projects across therapeutic areas, modalities and technologies, including pipeline optimization, go-to-market strategies, BD and M&A due diligence. Brendan’s research at Stanford Computer Science, University of Toronto and Trinity College Dublin focused on computational methods of small molecule drug discovery for oncology and neuroscience targets. With his background in research and strategy, Brendan is keenly Interested in the intersection of innovative science, company formation and strategy, particularly in the pursuit of new therapeutics for patients in need. * Education: Ph.D. Medicinal Chemistry, Trinity College Dublin Postdoc Computational Drug Discovery, Stanford University Postdoc Neuroscience Drug Discovery, University Health Network, University of Toronto * Sector: Biopharmaceuticals * Location: Boston Young Kwon, Ph.D. Advisor Young Kwon, Ph.D. Advisor Young Kwon, Ph.D. Advisor Young is an Advisor to LSV. He assists the LSV biopharmaceutical team with deal sourcing, due diligence, and portfolio company management. He initially joined LSV in April 2021 as an Operating Partner. Young is an accomplished executive with significant operating and venture capital experience. He is currently the Chief Financial and Operating Officer at Alchemab Therapeutics, an LSV portfolio company focused on developing novel antibody therapeutics generated from patients resilient to disease. Young is also a member of the board of directors of ADMA Biologics, (Nasdaq: ADMA), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics. Young held a variety of leadership roles over ten years as a senior executive at Momenta Pharmaceuticals, a public biotech company, prior to its sale to Johnson & Johnson for $6.5 billion. Young was most recently Chief Financial and Business Officer at Momenta, where he had responsibility for business development, strategy, finance, investor relations, and commercial. Young led public equity financings raising nearly $500 million, and led the company’s sale to J&J. Prior to Momenta, Young was a business development professional at Biogen, driving a variety of transactions. Young previously worked at Advanced Technology Ventures, working with the team on investments including Acceleron, Five Prime, Hypnion, and Zeltiq * Education: Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University B.S. in Biology from MIT * Sector: Biopharmaceuticals * Location: Boston Kenneth D. Noonan, Ph.D. CEO Lightstone Singapore PTE. LTD. Kenneth D. Noonan, Ph.D. CEO Lightstone Singapore PTE. LTD. Kenneth D. Noonan, Ph.D. CEO Lightstone Singapore PTE. LTD. Ken is currently the CEO of Lightstone Singapore Pte, Ltd. Previously Ken was a consultant to the life science industry. Most recently he was a senior partner and head of the European Life Sciences Practice at L.E.K. Consulting LLP. Prior to that he was a partner in the pharmaceutical practice at Booz-Allen & Hamiliton. Ken was also the founding partner and head of the European practice at The Wilkerson Group Ltd. Ken’s operating experience in discovery includes management roles at Cooper Life Sciences (to include Technicon), Becton Dickinson and Bethesda Research Labs. Ken has served as a Board member of both public and private life science companies in Europe and the U.S. to include Intercept Pharmaceuticals Inc., Kailos Genetics and Orchid Biosciences. During his academic career Ken authored more than 50 articles on the role of the cell surface in cell division. * Education: B.S. in Biology from St. Joseph’s University Ph.D. in Biochemistry from Princeton University * Sector: Biopharmaceuticals * Location: Singapore REPRESENTATIVE INVESTMENTS: * Ligature Therapeutics * MediSix Therapeutics Travis Boettner CFO & CCO Travis Boettner CFO & CCO Travis Boettner CFO & CCO Travis joined the Lightstone Ventures and Advanced Technology Ventures finance team in 2018. Travis is responsible for all aspects of accounting, tax, reporting, and compliance for LSV and ATV. Travis also serves as the Chief Financial Officer and Chief Compliance Officer at Morgenthaler Ventures, and Canvas Ventures. Travis began his career in PwC’s San Jose office where he spent five years in their Private Company Services group. * Education: B.S. in Management Science from the University of California, San Diego Certificate of Advanced Accounting Proficiency (CAAP) from Santa Clara University Certified Public Accountant (inactive) * Location: Menlo Park Caroline Gaynor Principal Caroline Gaynor Principal Caroline Gaynor Principal Caroline joined Lightstone Ventures in 2017 and evaluates new investment opportunities in the biopharmaceutical and medical device sectors out of the firm’s Dublin office. Caroline has over 10 years’ operational experience in the pharmaceutical industry. Caroline spent 9 years at Bayer Healthcare, most recently serving on the board of senior management of Bayer Ltd. Ireland as head of market access, pricing and reimbursement. During her time in pharma she held a number of operational roles, predominantly focused on oncology, such as product management, strategic marketing, business development and regulatory affairs. Prior to Lightstone, and following completion of her BioInnovate fellowship in 2013, she co-led R&D on a device targeting Acute Pancreatitis and was subsequently involved in early pre-clinical, strategic clinical and commercial development at Vetex Medical.. She currently serves as a director on the board of Catamaran Bio Ltd., Parvalis Therapeutics and ProVerum. She is an observer to the board of Carrick Therapeutics, Cerevance, and FIRE-1. She also previously served on the board of ALX Oncology. She is a member of the BioInnovate Ireland Board of advisors. * Education: B.S. in Pharmacy from Trinity College Dublin M.S. in Pharmaceutical Medicine from Trinity College Dublin M.S. in BioInnovation from National University of Ireland, Galway * Sector: Biopharmaceuticals, Medical Technology * Location: Dublin REPRESENTATIVE INVESTMENTS: * Catamaran Bio * Parvalis Therapeutics * Proverum Jingjing Wang, Ph.D. Senior Associate Jingjing Wang, Ph.D. Senior Associate Jingjing Wang, Ph.D. Senior Associate Jingjing is a senior associate at Lightstone Ventures evaluating new biopharma investment opportunities. Jingjing has a background in neurobiology and life sciences strategy. Before joining Lightstone, Jingjing was a Life Sciences Consultant at L.E.K. Consulting, where she worked on projects including target identification, opportunity assessment, corporate strategy, and commercial assessment for large pharmaceutical, mid-cap, and early-stage biotech companies. During her graduate studies, Jingjing was a senior fellow at the Office for Translation & Commercialization at Duke University assessing emerging technologies generated in laboratories at Duke. * Education: Jingjing attained her Ph.D. in neurobiology at Duke University. Her research focused on the molecular and cellular mechanisms of retinal neural circuit formation and glial network development. With an integrated background in sciences and business, Jingjing is excited to help advance innovative life-changing therapeutics for patients in need. * Sector: Biopharmaceuticals * Location: Boston Wen Qi Ho, Ph.D. Vice President Wen Qi Ho, Ph.D. Vice President Wen Qi Ho, Ph.D. Vice President Wen Qi is a Vice President at Lightstone Singapore Pte. Ltd., where she evaluates new investment opportunities in the biopharmaceutical and medical device sectors out of the firm’s Singapore office. She currently serves as a director on the board of Ligature Therapeutics Pte. Ltd. Wen Qi attained her B.Sc. in Molecular and Cellular Biology at Johns Hopkins University, and her Ph.D. in Immunology at Stanford University. She was also the recipient of the National Science Scholarship from the Agency for Science, Technology, and Research (A*STAR) Singapore. * Education: Ph.D. in Immunology from Stanford University B.Sc. in Molecular and Cellular Biology from Johns Hopkins University * Sector: Biopharmaceuticals * Location: Singapore REPRESENTATIVE INVESTMENTS: * Ligature Therapeutics Yvonne Koh, Ph.D. Associate Yvonne Koh, Ph.D. Associate Yvonne Koh, Ph.D. Associate Yvonne is an Associate at Lightstone Singapore Pte Ltd where she supports the team in evaluating and driving venture investment opportunities in the biopharmaceutical and medical device sectors. Prior to Lightstone, she was Deputy Director at the National Research Foundation, a division of the Prime Minister’s Office Singapore, where she led the formulation of innovation policy, implemented innovation grants and managed various technology translation platforms in the life sciences sector. Yvonne was also the Vice-President of Biotech Connection Singapore, where she worked closely with innovators, community leaders, academics and investors in shaping a vibrant life sciences startup ecosystem in Singapore. Yvonne holds a Ph.D. in Biochemistry from the University of Wisconsin, Madison and a B.Sc. from the University of Illinois, Urbana Champaign. She was a recipient of the National Science Scholarship from the Agency for Science, Technology and Research (A*STAR) Singapore. * Education: Ph.D. in Biochemistry from University of Wisconsin, Madison B.Sc. in Molecular and Cellular Biology from University of Illinois, Urbana Champaign Sector: Biopharmaceuticals * Sector: Biopharmaceuticals * Location: Singapore Olivia Peter Vice President, Finance Olivia Peter Vice President, Finance Olivia Peter Vice President, Finance Olivia joined the Lightstone Ventures finance team in 2022. She was previously part of the Lightstone Ventures Singapore team, which she joined in 2017, with her most recent role being the Director of Operations. She began her career at PricewaterhouseCoopers Singapore where she focused on the financial services industry, specializing in the provision of regulatory advisory and audit services to banks and asset managers. * Education: Bachelor of Accounting from Nanyang Technological University, Singapore Certified Public Accountant (Australia) * Location: Menlo Park Susan Molineaux, Ph.D. Scientific Advisor Susan Molineaux, Ph.D. Scientific Advisor Susan Molineaux, Ph.D. Scientific Advisor Dr. Molineaux is the co-founder, President and CEO of Calithera Biosciences, a start-up company that commenced operations in June of 2010. Prior to starting Calithera, Dr. Molineaux was a co-founder of Proteolix and served as the CSO for two years before becoming President and CEO of the company. Proteolix was acquired by Onyx Pharmaceuticals in November 2009. Prior to joining Proteolix, Dr. Molineaux was Vice President of Biology at Rigel Pharmaceuticals from 2000 to 2003. Before that, she was Vice President of Biology at Praelux, and from 1994 through 1999, Dr. Molineaux served as Vice President of Drug Development at Praecis Pharmaceuticals. From 1989 until 1994 she was a scientist in the immunology group at Merck, in Rahway, NJ. * Education: B.S. in Biology from Smith College Ph.D. in Molecular Biology from Johns Hopkins University Postdoctoral fellowship at Columbia University * Sector: Biopharmaceuticals * Location: Menlo Park Jaume Pons, Ph.D. Scientific Advisor Jaume Pons, Ph.D. Scientific Advisor Jaume Pons, Ph.D. Scientific Advisor Dr. Pons currently serves as the President and Chief Executive Officer of ALX Oncology. He previously served as Chief Scientific Officer and site head of Rinat (Pfizer), where he was responsible for portfolio delivery from idea to clinical development. He implemented the vision of a company unit following biology across therapeutic areas while generating advanced antibody technologies and turned Rinat into the center of cancer immunology for Pfizer. Dr. Pons is an inventor of fremanezumab, which was approved by the FDA in 2018, as well as two other antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. As Senior Vice President of R&D, he was a member of Pfizer’s World R&D Leadership Team. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron. * Education: Ph.D. in Molecular and Cell Biology from the Institute on Fundamental Biology, Barcelona M.S. in Biotechnology from Autonoma University of Barcelona B.S. in Biochemistry from Autonoma University of Barcelona Postdoctoral studies in Antibody Engineering from the University of California, Berkeley * Sector: Biopharmaceuticals * Location: Menlo Park Doug Treco, Ph.D. Scientific Advisor Doug Treco, Ph.D. Scientific Advisor Doug Treco, Ph.D. Scientific Advisor Doug Treco, PhD, was a co-founder of Ra Pharmaceuticals, Inc. in 2008 and served as Chief Executive Officer and a member of the Board of Directors from its inception until its acquisition by UCB in April 2020. Previously, he was an Entrepreneur-in-Residence at Morgenthaler Ventures from January 2008 to May 2014. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT), a multi-platform biopharmaceutical company developing protein and gene therapy products, which was acquired by Shire Pharmaceuticals Group plc in 2005. Dr. Treco was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School from 2004 to 2007. He received his Ph.D. in Biochemistry and Molecular Biology from the State University of New York at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital. * Sector: Biopharmaceuticals * Location: Boston REPRESENTATIVE INVESTMENTS: * Ra Pharmaceuticals Hong I. Wan, Ph.D. Scientific Advisor Hong I. Wan, Ph.D. Scientific Advisor Hong I. Wan, Ph.D. Scientific Advisor Hong I. Wan, Ph.D. is president, chief executive officer and co-founder of Tallac Therapeutics. Previously as chief scientific officer and a member of the founding management at ALX Oncology, she led the team to advance ALX148, a best-in-class myeloid checkpoint inhibitor, for multiple tumor indications. Prior to ALX Oncology, Dr. Wan held various leadership positions at Pfizer and Wyeth Research, where she was responsible for the early development and translational medicine strategy and execution across various therapeutic areas. Dr. Wan started her career at Renovis where she led discovery programs in neuroinflammation * Education: Ph.D. in Molecular and Cell Biology from University of California, Berkeley A.B. in Biochemical Sciences from Harvard University * Sector: Biopharmaceuticals * Location: Menlo Park Samira Kaissi, Ph.D. Entrepreneur in residence Samira Kaissi, Ph.D. Entrepreneur in residence Samira Kaissi, Ph.D. Entrepreneur in residence Samira started her career in California with a Ph.D. and postdoc in Molecular Biology (Viral Gene therapy) from USC and UCLA. Her journey has since spanned three continents and grew into various leadership roles such as national support manager and global marketing manager at Beckman Coulter in the United States; assistant professor and director of research at the American University of Beirut Medical Center; and finally to Ireland where she was a Site Lead at Becton Dickenson-Gencell and director of BD’s Research Center Ireland. Recently she held multiple CEO roles at medical device startups such as Cala Medical (developing a novel blood purification cartridge for sepsis) and Capri Medical (developing an implantable neurostimulation device for migraines). She also works with Enterprise Ireland as a commercial lead to support potential spinouts from Irish universities. Samira continues her foray into the exciting world of medtech and biotech entrepreneurship by joining the team at Lightstone Ventures as an EIR in 2022, where she hopes to play a role in transforming innovative ideas into health improving and life saving products. * Education: Ph.D. in Molecular Biology from University of a Southern California B.S. in Biological Sciences from UC, Irvine * Sector: Medical Technology * Location: Dublin News THE LATEST DEVELOPMENTS. 14 December, 2022 VIGIL NEUROSCIENCE ANNOUNCES FIRST PATIENT DOSED IN THE IGNITE PHASE 2 CLINICAL TRIAL TO EVALUATE VGL101 IN PATIENTS WITH ALSP 13 December, 2022 TAKEDA TO ACQUIRE NIMBUS THERAPEUTICS’ HIGHLY SELECTIVE, ALLOSTERIC TYK2 INHIBITOR TO ADDRESS MULTIPLE IMMUNE-MEDIATED DISEASES 1 December, 2022 CARRICK THERAPEUTICS ANNOUNCES $35 MILLION INVESTMENT FROM PFIZER 30 November, 2022 NIMBUS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FOR PHASE 2B CLINICAL TRIAL OF ALLOSTERIC TYK2 INHIBITOR IN PSORIASIS 17 November, 2022 ADVICE FOR ENTREPRENEURS IN THE MEDICAL DEVICE INDUSTRY ON RAISING CASH AND GROWING STARTUPS 11 November, 2022 TALLAC THERAPEUTICS PRESENTS DATA FOR TWO, FIRST-IN-CLASS TOLL-LIKE RECEPTOR 9 AGONIST ANTIBODY CONJUGATES AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 37TH ANNUAL MEETING 2 November, 2022 VIGIL NEUROSCIENCE ANNOUNCES INTERIM TOPLINE RESULTS FROM ITS ONGOING PHASE 1 CLINICAL TRIAL EVALUATING VGL101 IN HEALTHY VOLUNTEERS SUPPORTING PHASE 2 INITIATION IN ALSP 1 November, 2022 VIGIL NEUROSCIENCE RECEIVES FDA FAST TRACK DESIGNATION FOR VGL101 FOR THE TREATMENT OF PATIENTS WITH ALSP 28 October, 2022 AND THE BEST MEDICAL DEVICE INNOVATION OF 2022 GOES TO… 26 October, 2022 NIMBUS THERAPEUTICS APPOINTS NATHALIE FRANCHIMONT, M.D., PH.D., AS CHIEF MEDICAL OFFICER 11 October, 2022 NIMBUS THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH LILLY FOR SMALL MOLECULE ACTIVATORS OF AMPK 3 October, 2022 CALA HEALTH’S REAL-WORLD STUDY VALIDATES ITS WEARABLE’S LONG-TERM EFFICACY 14 September, 2022 CLAVYSTBIO LAUNCHES TO TRANSLATE LIFE SCIENCES BREAKTHROUGHS INTO HEALTH IMPACT 6 September, 2022 EARLENS SHARES FDA HISTORICAL RULING ON OTC HEARING AIDS 12 August, 2022 VIGIL NEUROSCIENCE ANNOUNCES $75 MILLION PRIVATE PLACEMENT FINANCING 10 August, 2022 GEMINI THERAPEUTICS AND DISC MEDICINE ANNOUNCE MERGER AGREEMENT 9 August, 2022 MERCK IS BACK IN ALZHEIMER’S SADDLE WITH $1B+ CEREVANCE PACT, YEARS AFTER DROPPING THE BACE 28 July, 2022 VIGIL NEUROSCIENCE STRENGTHENS BOARD OF DIRECTORS WITH APPOINTMENT OF SUZANNE BRUHN, PH.D. 28 July, 2022 TALLAC THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH TAC-001, A FIRST-IN-CLASS TOLL-LIKE RECEPTOR 9 AGONIST ANTIBODY CONJUGATE, IN A PHASE 1/2 STUDY FOR PATIENTS WITH ADVANCED SOLID TUMORS 13 June, 2022 NBC NEWS’ TODAY FEATURES THE MINIMALLY INVASIVE INTRACEPT® PROCEDURE FOR CHRONIC VERTEBROGENIC LOW BACK PAIN 13 June, 2022 PROVERUM: FIRST ENROLMENT IN THE PROVIDE CLINICAL STUDY FOR BPH TREATMENT 10 June, 2022 CALA HEALTH TACKLES HAND TREMORS WITH BIOELECTRONIC TREATMENT 7 June, 2022 VIGIL NEUROSCIENCE EXPANDS VGL101 PHASE 1 TRIAL TO AUSTRALIA 5 June, 2022 CYT-0851 PHASE 1 DOSE ESCALATION RESULTS SHOW EARLY CLINICAL ACTIVITY AND GENERALLY WELL TOLERATED SAFETY PROFILE IN ADVANCED SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES 23 May, 2022 GENE THERAPY LOWERS TOXIC RNA DUE TO C9ORF72 MUTATIONS IN ALS 23 May, 2022 SK BIOPHARMACEUTICALS PARTNERS WITH CALA TO FUEL INNOVATION IN NEUROLOGY 19 May, 2022 TALLAC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR TAC-001, A FIRST-IN-CLASS TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ANTIBODY CONJUGATE FOR PATIENTS WITH ADVANCED SOLID TUMORS 16 May, 2022 CATAMARAN BIO PRESENTS PRECLINICAL DATA SUPPORTING NOVEL ENGINEERED CAR-NK CELL THERAPIES FOR TREATING SOLID TUMORS 6 May, 2022 NEW DEVICE AIMS TO PROVIDE BETTER SOUND THAN HEARING AIDS 27 April, 2022 CATAMARAN BIO APPOINTS CHERRY THOMAS, MD, AS CHIEF MEDICAL OFFICER 20 April, 2022 VIGIL NEUROSCIENCE EXPANDS LEADERSHIP TEAM AND BOARD OF DIRECTORS 13 April, 2022 RALEIGH MEDICAL DEVICE COMPANY CONTEGO MEDICAL RAISES MORE THAN $15M 5 April, 2022 WILLOW INNOVATIONS, INC. LAUNCHES “REGISTER FOR MORE” CAMPAIGN; ENLISTS COMEDIAN AND NEW MOM ILIZA SHLESINGER TO CREATE ITS FIRST TV AD 5 April, 2022 CATAMARAN BIO APPOINTS FRANK LEE AS CHAIR OF ITS BOARD OF DIRECTORS 4 April, 2022 NEW RESEARCH PRESENTED AT AAN DEMONSTRATES BURDEN ASSOCIATED WITH ESSENTIAL TREMOR AND THE UNMET PATIENT NEED 29 March, 2022 WILLOW® EXPANDS PRODUCT SUITE AND UNVEILS WILLOW GO™, ITS FULLY IN-BRA WEARABLE BREAST PUMP FOR ONLY $329 28 March, 2022 CALA HEALTH ANNOUNCES NEW CHIEF COMMERCIAL, FINANCIAL OFFICERS AMID LEADERSHIP EXPANSION 14 March, 2022 CATAMARAN BIO EXPANDS COLLABORATION FOR CAR‑NK CELL ENGINEERING WITH THE UNIVERSITY OF MINNESOTA AND SECURES AN EXCLUSIVE PATENT LICENSE TO NEXT GENERATION MANUFACTURING TECHNOLOGIES 14 March, 2022 SHOULDER INNOVATIONS ANNOUNCES FDA CLEARANCE OF NEW INSET™ STEMLESS HUMERAL IMPLANT 1 March, 2022 CALA HEALTH IS BUILDING MOMENTUM BY EXPANDING AFFORDABLE ACCESS FOR PATIENTS WITH ESSENTIAL TREMOR 28 February, 2022 CATAMARAN BIO ANNOUNCES APPOINTMENT OF MICHAEL DERIDDER, PHD, AS SENIOR VICE PRESIDENT, CORPORATE STRATEGY AND NEW PRODUCT PLANNING 8 February, 2022 CYTEIR THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 WITH CYT-0851 7 February, 2022 CYTEIR THERAPEUTICS ANNOUNCES THE APPOINTMENT OF JOHN F. THERO TO BOARD OF DIRECTORS 12 January, 2022 CYTEIR THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 COMBINATION TRIAL WITH CYT-0851 11 January, 2022 PROVERUM RAISES €30M IN SERIES A FUNDING LED BY GILDE HEALTHCARE & LIGHTSTONE VENTURES 11 January, 2022 THE TOP 25 WOMEN LEADERS IN MEDICAL DEVICES OF 2022 7 January, 2022 VIGIL NEUROSCIENCE ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING 6 January, 2022 NIMBUS THERAPEUTICS ANNOUNCES EXPANSION OF ORAL ALLOSTERIC TYK2 INHIBITOR PROGRAM AND PROVIDES ADDITIONAL BUSINESS UPDATES 3 January, 2022 RELIEVANT MEDSYSTEMS’ INTRACEPT RECEIVES NEW CPT CODES TO AID REIMBURSEMENT EFFORTS * 1 * 2 * 3 * 4 * 5 * 6 * 7 * 8 * 9 * 10 20222021202020192018 Older Contact WE’RE HERE. REACH OUT. MENLO PARK LSV Capital Management, LLC. 2884 Sand Hill Road, Suite 121 Menlo Park, CA 94025 * T 650 388 3676 * F 650 388 3675 BOSTON LSV Capital Management, LLC. 500 Boylston St. Suite 1380 Boston, MA 02116 * T 617 933 3770 * F 617 933 3769 IRELAND Lightstone Capital Management Ireland, Ltd. 9 Pembroke Street Dublin 2 SINGAPORE Lightstone Singapore Pte, Ltd. OCBC Centre #27-07, 65 Chulia St Singapore 049513 Copyright 2022 Lightstone Ventures – All rights reserved * Terms and Conditions